TherapeuticsMD (TXMD) Enterprise Value (2011 - 2026)

TherapeuticsMD (TXMD) has reported Enterprise Value for 16 consecutive years, with $16.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Enterprise Value rose 122.78% year-over-year to $16.4 million; the trailing twelve-month figure through Jun 2026 stood at $16.4 million (up 122.78% YoY), and the FY2025 full-year result was $11.4 million, up 134.28% from the prior year.
• Enterprise Value climbed to $16.4 million in Q2 2026 per TXMD's latest filing, from $15.0 million in the prior quarter.
• Across five years, Enterprise Value topped out at $134.3 million in Q1 2022 and bottomed at -$7.5 million in Q4 2022.
• Historically, Enterprise Value has averaged $21.4 million across 5 years, with a median of $14.5 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Enterprise Value slumped 100.1% in 2022, then jumped 389.3% in 2023.
• Over 5 years, Enterprise Value stood at -$7.5 million in 2022, then surged by 389.3% to $21.6 million in 2023, then sank by 77.53% to $4.9 million in 2024, then soared by 134.28% to $11.4 million in 2025, then surged by 43.99% to $16.4 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered $16.4 million, $15.0 million, and $11.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.